Behnaz Eftekhari | Vascular Graft | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Behnaz Eftekhari
Scripps Health

Behnaz Eftekhari
Affiliation Scripps Health
Country United States
Google Scholar ID y4E5AmQAAAAJ&hl
Documents 31
Citations 676
h-index 11
Subject Area Vascular graft
Event International Research Awards on Cardiology & Cardiovascular Medicine

Behnaz Eftekhari is presented in this recognition profile in connection with research activity spanning biomaterials, tissue engineering, regenerative medicine, and vascular-related applications. Publicly available professional information identifies Eftekhari with Scripps Research and describes work involving biomaterials and translational research, while published literature under the name Behnaz Sadat Eftekhari documents contributions to engineered biomaterial systems and regenerative medicine. [1] The supplied bibliometric record reports 31 documents, 676 citations, and an h-index of 11.

Abstract

Behnaz Eftekhari is a biomedical researcher whose documented scholarly activities encompass biomaterials, tissue engineering, regenerative medicine, and translational research. Her publication record includes investigations of engineered polymeric and hydrogel systems, cellular microenvironments, conductive biomaterials, and regenerative applications. These areas intersect with contemporary cardiovascular and vascular engineering through the development of materials and biological interfaces designed to support tissue function and repair. Publicly available professional information also associates Eftekhari with Scripps Research and describes expertise in biomaterials and product development. [1] The supplied research metrics report 31 documents, 676 citations, and an h-index of 11, providing a quantitative basis for this recognition profile.

Keywords

Behnaz Eftekhari; Innovative Research Award; biomaterials; vascular grafts; tissue engineering; regenerative medicine; hydrogel systems; biomedical engineering; biomaterial scaffolds; cardiovascular medicine; translational research; cellular microenvironment.

Introduction

Biomedical engineering increasingly integrates materials science with cellular and tissue biology to address clinically relevant problems. Eftekhari’s documented research sits within this interdisciplinary environment, particularly through studies of biomaterial matrices, engineered substrates, hydrogels, and tissue-regenerative systems. Such research provides a scientific foundation for considering material design, biological compatibility, and functional tissue interactions in translational biomedical applications. [2]

Research Profile

Eftekhari’s research profile is characterized by an interdisciplinary focus on biomaterials and tissue engineering. Publicly indexed publications under the name Behnaz Sadat Eftekhari include studies of chitosan-based conductive hydrogels, polymeric nanoparticles, mesenchymal stem-cell responses, and silk fibroin matrices. [2] Professional information additionally identifies experience in biomaterials science, product development, and translational research. [1]

Research Contributions

The documented research contributions include development and evaluation of biomaterial systems intended to influence cellular behavior and tissue regeneration. Published work has examined conductive chitosan-polyaniline hydrogels and their potential role in neural priming, while other research addresses polymeric nanoparticles for controlled drug delivery and silk fibroin matrices for cellular interaction and tissue regeneration. [2] These studies demonstrate an emphasis on material–cell interactions and biomedical translation.

Publications

The publicly indexed publication record associated with Behnaz Sadat Eftekhari includes peer-reviewed studies and reviews addressing biomedical materials and regenerative applications. Examples include Conductive chitosan/polyaniline hydrogel with cell-imprinted topography as a potential substrate for neural priming of adipose derived stem cells, published in RSC Advances, and Silk Fibroin-Based Matrices for the Guidance of Cell Interaction, Tissue Regeneration, and Crosstalk, published in Macromolecular Bioscience. [2] DOI information for these publications is provided in the references.

Research Impact

The supplied bibliometric information records 676 citations across 31 documents and an h-index of 11. These measures provide quantitative indicators of scholarly visibility within the supplied research record, although citation counts and h-index values can vary between databases and over time. The documented publication portfolio further indicates sustained engagement with biomaterials, cellular engineering, and regenerative medicine, areas relevant to translational biomedical research. [1]

Award Suitability

For the proposed Innovative Research Award, the documented record provides several relevant areas for committee consideration, including interdisciplinary biomaterials research, tissue-engineering applications, cellular microenvironment studies, and translational biomedical development. The research portfolio contains peer-reviewed contributions involving engineered materials and regenerative systems, while the supplied bibliometric indicators provide additional evidence of scholarly dissemination. Final award determination should remain subject to the official eligibility requirements and independent evaluation procedures of the International Research Awards on Cardiology & Cardiovascular Medicine.

Conclusion

Behnaz Eftekhari’s documented scholarly profile reflects interdisciplinary work at the intersection of biomaterials, tissue engineering, regenerative medicine, and biomedical research. Published studies demonstrate engagement with engineered matrices, hydrogels, nanoparticles, and cellular responses, while the supplied bibliometric record reports 31 documents, 676 citations, and an h-index of 11. Together, these materials provide a structured academic basis for consideration within an innovative research recognition framework.

References

  1. Elsevier. (n.d.). Scopus author details: Behnaz Eftekhari, Author ID 57198443389. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57198443389
  2. Review article (2026). Functionalization of graphene oxide and its applications in tissue engineering and regenerative medicine.
    https://doi.org/10.1016/j.bioadv.2025.214421
  3. World Health Organization. (2026 ). Cardiovascular diseases. World Health Organization.
    https://cardiology-conferences.pencis.com/

Yared Fanta | Case Reports | Research Excellence Award

Published on by Cardiology and Cardiovascular Medicine

Research Excellence Award

Yared Fanta
Woliyta Sodo University, Ethiopia

Yared Fanta
Affiliation Woliyta Sodo University
Country Ethiopia
Scopus ID 58755020500
Documents 2
Citations 23
h-index 2
Subject Area Case Reports
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0009-0008-2761-0956

Yared Fanta is affiliated with Woliyta Sodo University, Ethiopia, and is associated with research classified under Case Reports. The supplied Scopus profile records two documents, 21 citations, and an h-index of 2. These bibliometric indicators provide a concise representation of the indexed research record and are presented in the context of the Research Excellence Award associated with the International Research Awards on Cardiology & Cardiovascular Medicine. Bibliometric information can change as databases update author profiles, citation counts, and publication records.[1]

Abstract

This article presents an academic profile of Yared Fanta of Woliyta Sodo University, Ethiopia, in connection with the Research Excellence Award. The supplied researcher record identifies Case Reports as the subject area and reports two Scopus-indexed documents, 21 citations, and an h-index of 2. The profile is considered within the broader context of cardiology and cardiovascular medicine research. It summarizes the researcher’s institutional affiliation, bibliometric indicators, publication record, research contribution context, and potential relevance to academic recognition. The information is descriptive and based on the supplied researcher identifiers and profile data, without independent evaluation of research quality.

Keywords

Yared Fanta; Research Excellence Award; Woliyta Sodo University; Ethiopia; Case Reports; Cardiology; Cardiovascular Medicine; Scopus; Research Impact; Academic Recognition.

Introduction

Academic recognition profiles commonly combine institutional affiliation, publication activity, citation information, and researcher identifiers to provide a structured view of scholarly activity. In medical research, case reports can document clinically notable observations and contribute to professional knowledge. Yared Fanta’s supplied profile identifies Case Reports as the relevant subject area and associates the record with Woliyta Sodo University. The bibliometric information reported for the profile is used here as descriptive evidence of indexed scholarly activity rather than as an independent measure of research quality or clinical significance.[1]

Research Profile

Yared Fanta is identified as being affiliated with Woliyta Sodo University in Ethiopia. The supplied Scopus identifier is 58755020500, while the associated ORCID identifier is 0009-0008-2761-0956. The profile contains two documents, 21 citations, and an h-index of 2. These indicators represent the supplied bibliometric snapshot and may vary over time because citation databases continuously update publication and citation information.[1][2]

Research Contributions

The supplied subject classification of Case Reports indicates participation in a publication area focused on individual clinical observations and documented medical cases. Such reports may provide information concerning unusual presentations, diagnostic considerations, treatment experiences, or clinically relevant observations. However, the supplied data do not provide the titles, abstracts, methodologies, clinical findings, or detailed topics of the two documents. Specific research contributions therefore require verification against the underlying publications before particular findings or clinical implications can be attributed to the researcher.

Publications

The supplied Scopus record reports two documents associated with Yared Fanta’s author identifier. The available information does not include complete publication titles, journal details, publication dates, coauthor information, or DOI identifiers for those documents. Accordingly, this profile records the publication count without reconstructing a bibliography that has not been independently supplied. Further publication-level verification would allow the relationship between the reported case reports and cardiology or cardiovascular medicine to be examined more specifically.[1]

Research Impact

The supplied record contains 21 citations across two documents and reports an h-index of 2. Citation counts can provide an indication of how frequently indexed scholarly works have been cited, while the h-index combines publication and citation information into a single bibliometric measure. These indicators are dependent on database coverage, author identification, publication timing, and citation updates, and therefore should be interpreted as quantitative descriptors rather than comprehensive measures of research quality or broader academic influence.[1]

Award Suitability

The Research Excellence Award profile connects Yared Fanta’s supplied research record with the International Research Awards on Cardiology & Cardiovascular Medicine. The documented affiliation, subject classification, publication count, citation count, and researcher identifiers provide information that can be included in an academic recognition profile. Formal award eligibility or recognition should be determined according to the applicable nomination requirements, evaluation criteria, supporting evidence, and verification procedures published by the award organizer.[3]

Conclusion

Yared Fanta’s supplied academic profile identifies an affiliation with Woliyta Sodo University in Ethiopia and a research record classified under Case Reports. The reported Scopus indicators comprise two documents, 21 citations, and an h-index of 2. Together with the supplied ORCID and Scopus identifiers, these details provide a structured basis for an academic recognition profile associated with the Research Excellence Award. More detailed assessment of research contributions would require verification of the underlying publications and the formal criteria governing the award process.

References

  1. Elsevier. (n.d.). Scopus author details: Yared Fanta, Author ID 58755020500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58755020500
  2. Journal article (2024. ) Nutritional response to water hyacinth (Eichhornia crassipes) challenges via blood biochemical profiles in goats and sheep.
    https://doi.org/10.1016/j.heliyon.2024.e28424
  3. World Health Organization. (2026 ). Cardiovascular diseases. World Health Organization.
    https://cardiology-conferences.pencis.com/

Emilia D’Elia | Heart Failure | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Emilia D’Elia
ASST Papa Giovanni XXIII, Italy

Emilia D’Elia
Affiliation ASST Papa Giovanni XXIII
Country Italy
Scopus ID 40660899000
Documents 100
Citations 1,647
h-index 19
Subject Area Heart Failure
Event Cardiology and Cardiovascular Medicine
ORCID 0000-0002-6682-0074

Emilia D’Elia is a cardiovascular researcher affiliated with ASST Papa Giovanni XXIII in Italy, with a research profile focused on heart failure. The supplied bibliometric record reports 100 documents, 1,647 citations, and an h-index of 19, providing measurable indicators of scholarly productivity and visibility within cardiovascular medicine.[1]

Abstract

Emilia D’Elia is a cardiovascular researcher affiliated with ASST Papa Giovanni XXIII in Italy, with a documented research profile in heart failure. Available bibliometric information identifies 100 documents, 1,647 citations, and an h-index of 19, indicating sustained publication activity and measurable academic visibility. Her subject specialization places her work within contemporary cardiovascular medicine, where heart failure research addresses diagnosis, treatment, outcomes, and disease management. The profile provides a quantitative basis for considering research recognition while acknowledging that bibliometric indicators should be interpreted alongside publication quality, originality, clinical relevance, collaboration, and broader contributions to cardiovascular science and patient care.[1]

Keywords

Emilia D’Elia; heart failure; cardiology; cardiovascular medicine; clinical research; scholarly impact; bibliometrics; citations; h-index; cardiovascular outcomes; ASST Papa Giovanni XXIII; Italy; research recognition; Best Researcher Award.

Introduction

Heart failure is a major area of cardiovascular research requiring evidence across prevention, diagnosis, pharmacological management, device therapy, and long-term outcomes. Contemporary clinical guidance emphasizes multidisciplinary and evidence-based approaches to improving outcomes for affected patients.[2] Researchers specializing in heart failure contribute to the development and evaluation of clinically relevant evidence.

Research Profile

The supplied profile identifies Emilia D’Elia with ASST Papa Giovanni XXIII in Italy and associates her principal subject area with heart failure. Her Scopus author identifier is 40660899000, while the reported record comprises 100 documents, 1,647 citations, and an h-index of 19. These indicators describe a research profile with established bibliometric visibility.[1]

Research Contributions

The available information supports characterization of D’Elia’s research within heart failure and cardiovascular medicine. Research in this field can contribute to understanding disease mechanisms, improving risk assessment, evaluating therapeutic strategies, and strengthening evidence-based clinical care. The documented publication and citation record provides measurable evidence of sustained engagement with the scientific literature.[1]

Publications

The supplied Scopus information reports 100 documents associated with the researcher profile. Because individual publication titles, journals, publication years, and article-level identifiers were not provided, this article does not assign specific publications or DOIs without verification. The complete bibliographic record can be reviewed through the linked Scopus author profile.[1]

Research Impact

The reported 1,647 citations and h-index of 19 provide quantitative measures of scholarly influence within the indexed research record. Citation metrics can assist in evaluating research visibility, although they do not independently establish methodological quality, originality, clinical effectiveness, or societal benefit. A balanced assessment should therefore consider both bibliometric and qualitative evidence.[1]

Award Suitability

Based on the supplied information, Emilia D’Elia presents characteristics relevant to consideration for a Best Researcher Award in cardiology and cardiovascular medicine, particularly through her documented activity in heart failure research and established bibliometric record. Final award assessment should additionally consider originality, publication quality, research leadership, clinical relevance, collaboration, and independently verifiable achievements.

Conclusion

Emilia D’Elia’s supplied academic profile reflects sustained research activity in heart failure and cardiovascular medicine, supported by 100 reported documents, 1,647 citations, and an h-index of 19. These indicators provide a quantitative foundation for academic recognition, while a complete award evaluation should incorporate verified publication quality, scientific originality, clinical significance, and broader research contributions.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Emilia D’Elia, Author ID 40660899000. Scopus.
    https://www.scopus.com/pages/authors/40660899000
  2. Journal article (2025.). SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting.
    https://doi.org/10.1093/eurheartjsupp/suae117
  3. Journal article. (2026.). Sex-related disparities in elderly patients with heart failure with mildly reduced or preserved ejection fraction.
    https://doi.org/10.1093/eschf/xvaf022
  4. Cardiology and Cardiovascular Medicine. (2026.). International Cardiology and Cardiovascular Medicine event website.
    https://cardiology-conferences.pencis.com/

Runze Wen | Cardiac Imaging | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Runze Wen | Cardiac Imaging | Best Researcher Award

The First Affiliated Hospital of University of Science and Technology | China

Dr. Runze Wen is an emerging scholar in the field of Cardiac Nuclear Medicine, currently pursuing his doctoral degree at the University of Science and Technology of China. His research focuses on advancing nuclear imaging techniques for cardiovascular diagnostics, with a strong emphasis on enhancing the precision and clinical applicability of cardiac assessments. Despite being at an early stage in his academic career, Dr. Wen has already demonstrated remarkable productivity and impact within the scientific community, with 3 published documents, 13 citations across 13 referencing works, and an h index of 3, a clear indication of the relevance and influence of his research. His investigations often integrate nuclear imaging modalities with innovative diagnostic approaches to improve the understanding of coronary microvascular dysfunction and other complex cardiac conditions. In addition to his academic achievements, Dr. Wen is a Fellow in Training (FIT) member of the American College of Cardiology (ACC), reflecting his commitment to professional development and international collaboration within the cardiology field. His ability to bridge advanced imaging science with clinical cardiology has earned him recognition as a promising young researcher dedicated to transforming cardiovascular diagnostics. Through his ongoing research and active engagement in academic circles, Dr. Runze Wen continues to contribute meaningfully to the future of nuclear cardiology, aiming to enhance patient care through evidence based innovation and interdisciplinary research excellence.

Profiles: Scopus | Orcid

Featured Publications

Wen, R., Xie, Q., Pan, B., Ni, M., Zhu, X., Meng, X., Wei, Z., Wu, X., Li, D., & Wang, X. (2025). Simultaneous 13N-ammonia and gadolinium perfusion using integrated PET–MRI: Diagnostic accuracy in coronary microvascular dysfunction. Frontiers in Medicine

Wen, R., Zhao, M., Chen, C., Yang, Y., & Zhang, B. (2023). A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate- and high-risk differentiated thyroid cancer patients: A bi-center retrospective study.

Hajime Kataoka | Heart Failure | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Hajime Kataoka | Heart Failure | Best Researcher Award

Nishida Hospital | Japan

Dr. Hajime Kataoka is a distinguished Cardiologist and Physician-Scientist at Nishida Hospital, Oita, Japan, widely recognized for his pioneering contributions to cardiovascular medicine. He has devoted his career to advancing the understanding, diagnosis, and treatment of cardiovascular diseases, with particular expertise in clinical electrocardiography and heart failure. His research focuses on body fluid status and cardio-renal interactions in patients with heart failure, exploring how electrolyte balance influences cardiac function and disease progression. Dr. Kataoka is best known for developing the groundbreaking “chloride theory” of heart failure pathophysiology, which redefines traditional perspectives by emphasizing chloride’s key role in regulating body fluid distribution and congestion, surpassing the conventional sodium-based understanding. This innovative theory has significantly influenced modern approaches to assessing diuretic response, predicting prognosis, and optimizing treatment strategies in heart failure management. With 107 published documents, 1,101 citations from 816 citing documents, and an h-index of 19, Dr. Kataoka has made a lasting impact on cardiovascular research and clinical practice. His scientific insights continue to inspire new investigations into electrolyte physiology, fluid regulation, and therapeutic innovation, solidifying his reputation as a thought leader in contemporary cardiology and as a driving force behind transformative advances in the field.

Profiles: Scopus | Orcid

Featured Publications

Kataoka, H. (2023). Acetazolamide as a potent chloride-regaining diuretic: Time to re-evaluate its diverse actions. Polish Archives of Internal Medicine.

Kataoka, H. (2022). Estimation of plasma renin activity on the basis of serum and urinary chloride concentrations versus sodium concentrations. Cardiorenal Medicine.

Kataoka, H. (2022). Mechanistic insights into chloride-related heart failure progression according to the plasma volume status. ESC Heart Failure.

Kataoka, H. (2020). Comparison of changes in plasma volume and renal function between acetazolamide and conventional diuretics: Understanding the mechanical differences according to their effects. Cardiology.

Kataoka, H., & Yoshida, Y. (2020). Enhancement of the serum chloride concentration by administration of sodium-glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: A pilot study. Diabetology & Metabolic Syndrome.

Yajie Liu | Cardiac Imaging | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Yajie Liu | Cardiac Imaging | Best Researcher Award

Peking University Shenzhen Hospital | China

Author Profile:

Scopus

Orcid

🌟Prof. Dr. Yajie Liu – A Pioneer in Radiation Oncology & Cancer Research Excellence

🎓 EARLY ACADEMIC PURSUITS

Dr. Yajie Liu began her medical journey with a Bachelor of Medicine (1985–1990) from Norman Bethune University of Medical Sciences. Driven by a deep interest in oncology, she completed her Master's degree in Oncology (1993–1996) from Harbin Medical University, followed by a prestigious Ph.D. in Oncology (1998–2001) at the Peking Union Medical College.

To expand her global medical perspective, she completed a Visiting Scholar Fellowship in Radiation Oncology at Chonnam National University Hospital in South Korea in 2010.

🏥 PROFESSIONAL ENDEAVORS

Dr. Liu's medical career spans over three decades of dedicated clinical service and leadership:

  • 1990–1992: Resident Physician, ENT, First Workers' Hospital of Liaohe Petroleum Exploration Bureau

  • 1992–1998: Resident & Attending Physician, Radiation Oncology, The Third Affiliated Hospital of Harbin Medical University

  • 2001–2017: Progressed from Attending to Chief Physician and Deputy Director at Shenzhen People’s Hospital

  • 2017–Present: Chief Physician and Director, Department of Radiation Oncology, Peking University Shenzhen Hospital

Her ascent to leadership reflects a consistent trajectory of clinical excellence and patient-centered care in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC IMAGING

Dr. Liu has led and co-led numerous research projects focused on:

  • Radiosensitization in Cancer Therapy

  • Hyperthermia and Serum Biomarkers

  • Radiation-Induced Brain Injury

  • Gene Assays for Breast Cancer Prognosis

  • Advanced Radiotherapy Strategies for Rectal and Colorectal Cancer

She has actively participated in national-level research, contributing to the Ministry of Science & Technology's high-impact projects on biomarkers and innovative radiotherapy techniques.

💡 RESEARCH FUNDING & PROJECT LEADERSHIP

As Principal Investigator (PI):

  • Shenzhen Science & Technology Bureau (4 Projects)

  • Shenzhen Health Commission (1 Project)

  • International Collaboration Grant (¥500K)

These funded projects demonstrate her innovative approach in blending clinical insight with technological advancement, especially in plasma therapy and hypoxic tumor sensitization.

🌐 PROFESSIONAL LEADERSHIP & ACADEMIC SERVICE

Dr. Liu holds key roles in multiple national and regional medical bodies:

  • Standing Committee Member, CRTOG

  • Committee Member, Radiotherapy Branch, Chinese Medical Doctor Association

  • Vice Chair, Lung Cancer Committee, Guangdong Women Doctors’ Association

  • Director, Radiotherapy Branch, Shenzhen Anti-Cancer Association

  • Council Member, Jiusan Society Shenzhen Chapter

Her positions reflect widespread recognition of her expertise and leadership in oncology.

📚 ACADEMIC CITES & COLLABORATIONS

While specific citation metrics are not provided here, Dr. Liu’s work on biomarkers, 21-gene assays, radiation injury, and colorectal cancer radiosensitization has contributed to national and international collaborations, significantly enriching the literature in radiation oncology.

🌍 IMPACT AND INFLUENCE

Dr. Liu's multidisciplinary research has influenced clinical protocols, improved patient outcomes, and inspired young oncologists across China. Her work on low-temperature plasma in radiosensitization reflects her commitment to cutting-edge translational oncology.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yajie Liu's legacy is marked by:

  • Pioneering radiotherapy techniques

  • Mentoring future oncology leaders

  • Driving forward international research collaborations

Her future direction is expected to focus on precision oncology, AI-guided radiotherapy planning, and expanding patient-centered cancer care models.

📑 NOTABLE PUBLICATIONS

"Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress"

Authors: M Yang, D Shi, J Lyu, Y Pan, Y Lyv, X Chen, Y Ouyang, Y Liu, Y Li, L Song
Journal: Redox Biology
Year: 2025

"X-ray-activated nanoscintillators integrated with tumor-associated neutrophils polarization for improved radiotherapy in metastatic colorectal cancer"

Authors: H Li, J Zeng, Q You, M Zhang, Y Shi, X Yang, W Gu, Y Liu, N Hu, Y Wang, X Chen, J Mu
Journal: Biomaterials
Year: 2025

Yan Zhang | Cardiovascular diseases | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Yan Zhang | Cardiovascular diseases | Best Researcher Award 

Prof. Yan Zhang, Affiliated Hospital,Liaoning University of Traditional Chinese Medicine, China

Prof. Yan Zhang is a distinguished researcher and medical expert at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China. With extensive experience in Traditional Chinese Medicine (TCM), her research focuses on integrative medicine, herbal formulations, and their clinical applications. She has contributed significantly to the advancement of TCM through numerous publications and collaborative projects. Prof. Zhang is dedicated to bridging modern medical practices with ancient healing traditions, enhancing patient care and treatment efficacy. Her work plays a crucial role in promoting evidence-based TCM approaches for various health conditions, fostering innovation in holistic healthcare solutions.

AUTHOR PROFILE

Scopus Profile

✨ EARLY ACADEMIC PURSUITS:

Prof. Yan Zhang embarked on an illustrious academic journey in Traditional Chinese Medicine (TCM). His foundational education began at Liaoning College of Traditional Chinese Medicine, where he earned a Bachelor’s Degree in Traditional Chinese Medicine (1978-1983). His keen interest in advancing his expertise led him to pursue a Master’s Degree in Typhoid Fever (1986-1989) from the same institution. Determined to further his knowledge, he obtained a Ph.D. in Internal Medicine (2001-2004) from Beijing University of Chinese Medicine, one of China’s most prestigious institutions for TCM studies.

👩‍🎓 PROFESSIONAL ENDEAVORS:

Prof. Zhang’s professional career spans over four decades, marked by dedication and leadership. His significant roles include:

  • Chief Physician (Since 2012): He has been leading the Cardiopulmonary Department at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.
  • Director of the Department of Research (2006-2012): At the same hospital, he oversaw groundbreaking medical research and contributed to numerous advancements in TCM.
  • Director of Internal Medicine (1989-2001): He served as the Director of the Department of Traditional Chinese Medicine Internal Medicine at the Liaoning College of Traditional Chinese Medicine Affiliated Hospital.
  • Early Medical Practice (1983-1986): His career began as a Doctor in the Department of Internal Medicine at Dandong City Traditional Chinese Medicine Hospital.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Prof. Zhang is a pioneer in Traditional Chinese Medicine, with a specialized focus on cardiovascular diseases. His research revolves around integrating modern medical techniques with traditional healing practices, making significant strides in the treatment of cardiopulmonary disorders. As an academic leader of China’s national key discipline for cardiovascular research, he has spearheaded numerous studies and projects that have influenced the field profoundly.

He is an expert evaluator for major scientific organizations, including:

  • China’s National Natural Science Foundation Projects
  • China’s National Science and Technology Awards

His contributions have been instrumental in shaping national policies and advancements in TCM research.

🌟 IMPACT AND INFLUENCE:

Prof. Zhang’s influence extends beyond his hospital and university. His expertise has earned him several prestigious accolades, including:

  • Renowned Traditional Chinese Medicine Practitioner of Liaoning Province
  • Outstanding Talent & Expert of Liaoning Province
  • Advanced Scientific and Technological Worker in Liaoning Province
  • Recipient of the Special Allowance of the State Council of China

His mentorship has nurtured numerous doctoral candidates, ensuring that the future of Traditional Chinese Medicine remains in capable hands.

📚 ACADEMIC CITES:

Prof. Zhang’s extensive research and scholarly contributions have been widely cited in various national and international medical journals. His work on cardiovascular health, herbal medicine formulations, and the integration of TCM with modern science has set a benchmark for medical professionals worldwide.

🌟 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Zhang’s legacy in Traditional Chinese Medicine is monumental. His future contributions aim to:

  • Develop new treatment methodologies that combine Western and Eastern medical practices.
  • Mentor the next generation of TCM practitioners.
  • Influence government health policies for the wider acceptance of TCM in mainstream healthcare.
  • Continue his groundbreaking research on cardiovascular diseases.

As a visionary leader in Traditional Chinese Medicine, Prof. Yan Zhang’s dedication, research, and teachings will continue to shape the medical landscape for generations to come.

✨CONCLUSION:

Prof. Yan Zhang’s dedication to Traditional Chinese Medicine (TCM) continues to shape the future of integrative healthcare. Through her research, clinical expertise, and innovative approaches, she bridges ancient wisdom with modern medical advancements, ensuring better patient outcomes . Her contributions not only enhance TCM’s credibility worldwide but also inspire future generations of practitioners and researchers. With a passion for holistic healing and evidence-based medicine, Prof. Zhang remains a key figure in promoting natural therapies for global health and wellness. Her work stands as a testament to the enduring power of TCM in modern medicine.

TOP NOTABLE PUBLICATION

Mechanism of Ferroptosis in Regulating Chronic Heart Failure and Traditional Chinese Medicine Prevention and Treatment Based on Qi Deficiency and Stagnation: A Review

Journal: Chinese Journal of Experimental Traditional Medical Formulae
Year: 2025

Mengchao Wei | Venous thromboembolism | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Mengchao Wei | Venous thromboembolism | Best Researcher Award

Dr. Mengchao Wei, Peking Union Medical College Hospital, China

Dr. Mengchao Wei is a physician at Peking Union Medical College Hospital, China, specializing in Urology. He graduated with a Doctor’s degree from Sun Yat-sen University in 2019. Since joining PUMCH in 2021, Dr. Wei has focused on optimizing perioperative management for urologic surgeries. He developed a predictive model for venous thromboembolism risk post-surgery, now integrated into clinical practice. Dr. Wei has published 10 journal articles in SCI and Scopus indexed journals. His research aims to improve patient safety and surgical outcomes, making significant contributions to the field of urologic surgery.

Author Profile

Orcid Profile

📚Early Academic Pursuits: 

Dr. Mengchao Wei graduated with a Doctor’s degree from Sun Yat-sen University in 2019. His academic journey laid the foundation for his current work, particularly in the field of Urology, where he became deeply involved in understanding the nuances of perioperative management in urologic surgeries. His comprehensive training and early research set him on a path to clinical excellence and innovation.

⚕️Professional Endeavors and Contributions: 

Since 2021, Dr. Wei has been practicing as a Physician at Peking Union Medical College Hospital, where his focus lies in the optimization of perioperative management in urologic surgeries. His clinical work has had a direct impact on improving patient care and the efficiency of surgical outcomes. Dr. Wei’s contributions include the development of a predictive model for venous thromboembolism risk following urologic surgeries, which has been implemented in real-world clinical practice to enhance patient safety.

🔬Research Focus and Innovations on Venous thromboembolism:

Dr. Wei’s research centers on perioperative management within urology, particularly concerning venous thromboembolism (VTE) risk. His predictive model for VTE risk, now utilized in clinical settings, showcases his ability to translate research into tangible, life-saving outcomes. While his citation index stands at 10, his work continues to gain attention in the medical community. He has published 10 journals in esteemed databases such as SCI and Scopus, reinforcing his status as a respected figure in urologic research.

🌍Impact and Influence: 

Dr. Wei’s contributions have not only benefited his hospital but also shaped the way urologic surgeries are managed perioperatively. By providing a tool that enhances clinical decision-making, he directly improves surgical outcomes, patient safety, and overall healthcare efficiency. His work has influenced peers, setting a new standard in the field of urology.

📑Academic Citations:

Dr. Wei has an impressive citation index of 10, a reflection of the growing recognition of his work and the clinical value it brings. His research continues to receive acknowledgment in relevant medical journals, contributing to the advancement of perioperative care in urology.

🚀Legacy and Future Contributions: 

Dr. Wei’s research and innovations indicate a promising future in the field of urology. He is committed to enhancing perioperative management for urologic surgeries and advancing clinical practices. Moving forward, his aim is to refine predictive models and further contribute to patient safety and surgical excellence.

🌟Conclusion:

Dr. Mengchao Wei’s work at Peking Union Medical College Hospital has made a significant impact on perioperative management in urologic surgeries. His predictive model for venous thromboembolism risk has been successfully integrated into clinical practice, improving patient outcomes and safety. With 10 journal publications in SCI and Scopus indexed journals, Dr. Wei is recognized as a dedicated and innovative physician. His contributions are shaping the future of urologic surgery. As he continues to push the boundaries of medical research, his work promises to enhance the quality of care and patient safety worldwide.

Top Notable Publications 

A nomogram predicting the risk of venous thromboembolism in patients following urologic surgeries

Authors: Mengchao Wei

Journal: Scientific Reports

Year: 2025

The role of antimicrobial prophylaxis in laparoscopic nephrectomy for renal cell carcinoma

Authors: Mengchao Wei

Journal: BMC Urology

Year: 2024

Comparison of AirSeal versus conventional insufflation system for retroperitoneal robot-assisted laparoscopic partial nephrectomy: a randomized controlled trial

Authors: Mengchao Wei

Journal: World Journal of Urology

Year: 2024

Surgery or external beam radiation for solitary small hepatocellular carcinoma

Authors: Mengchao Wei

Journal: Journal of Cancer Research and Therapeutics

Year: 2023

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy

Authors: Mengchao Wei

Journal: Frontiers in Oncology

Year: 2022

Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2022

The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer

Authors: Mengchao Wei

Journal: International Journal of Radiation Oncology, Biology, Physics

Year: 2022

Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2020

Radiofrequency ablation plus nucleotide analogues for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis

Authors: Mengchao Wei

Journal: American Journal of Translational Research

Year: 2018

Sorafenib versus Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Authors: Mengchao Wei

Journal: BMC Cancer

Year: 2018

Xingang Li | harmacology | Best Research Article Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Xingang Li | pharmacology | Best Research Article Award 

Prof. Xingang Li, Department of Pharmacy, Beijing Friendship Hospital, China

Prof. Xingang Li is the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, China, where he also serves as a Chief Pharmacist, Professor, and Ph.D. Supervisor. An expert in quantitative pharmacology and genetic pharmacology, Prof. Li has published over 50 articles in top-tier journals, with more than 1000 citations and an H-index of 20. He is an External Expert at the National Center for Drug Evaluation, a member of multiple prestigious pharmacological committees, and a reviewer for leading journals such as Biomaterials and Clin Transl Med. His research focuses on personalized medicine, drug delivery systems, and epigenetic influences on pharmacodynamics.

Profile:

Orcid Profile

🏥 Current Positions:

Prof. Li Xingang serves as the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, where he is also the Chief Pharmacist. As a Professor and Ph.D. Supervisor, he is instrumental in nurturing future generations of pharmacists and researchers. His leadership role involves overseeing advanced pharmacological practices, mentoring young scientists, and ensuring cutting-edge drug evaluation and management systems. With a strong emphasis on precision medicine, Prof. Li combines clinical expertise and research excellence to address pressing healthcare challenges.

📚 Academic Background:

Prof. Li has an extensive academic background, which underpins his outstanding contributions to quantitative pharmacology and genetic pharmacology. His role as an External Expert at the National Center for Drug Evaluation and Review Expert for the Beijing Science and Technology Plan Project showcases his authority in the field. His memberships in prestigious committees, such as the Quantitative Pharmacology Committee of the Chinese Pharmacological Society and the Epigenetics Committee, reflect his deep commitment to advancing pharmaceutical sciences.

🧪 Research Interests and Achievements:

Quantitative Pharmacology: Prof. Li has a keen interest in developing predictive models to optimize drug efficacy and safety, leveraging mathematical frameworks to personalize treatment.

Genetic Pharmacology: His research focuses on exploring genetic factors that influence drug metabolism and efficacy, aiming to enhance personalized medicine approaches.

Prof. Li has successfully led over ten major projects, including initiatives funded by the Ministry of Science and Technology, the National Natural Science Foundation, and the Beijing Science and Technology Plan. These projects address critical areas like drug delivery systems, personalized pharmacotherapy, and genetic determinants of drug response.

🖋️ Publication Achievements:

Prof. Li’s academic rigor is evident in his extensive publication record, with over 50 articles in Q1 journals such as Nano Letters, Acta Pharmacologica Sinica, and Phytomedicine. His works have been cited more than 1000 times, and he holds an impressive H-index of 20, reflecting his impact on the scientific community. His publications explore innovative drug delivery systems, genetic biomarkers, and clinical pharmacokinetics, contributing significantly to global pharmacological advancements.

🏆 Scholarships and Awards:

Prof. Li has received numerous accolades for his contributions:

  • Servier Young Hospital Pharmacy Award, China Pharmaceutical Society
  • Outstanding Pharmacist Award, Beijing Pharmaceutical Society
  • Recognized for Outstanding Papers and groundbreaking research, reflecting his excellence in clinical pharmacy and translational research.

🧑‍🔬 Professional Associations and Editorial Roles:

Prof. Li is actively involved in professional organizations, including the Chinese Pharmacological Society and the China Pharmaceutical Education Association. He serves as an Editorial Board Member for journals such as China Hospital Pharmacy Evaluation and Analysis and Chinese Pharmacy, ensuring the dissemination of high-quality research.

As a Reviewer for prestigious journals like Biomaterials and Clin Transl Med, he evaluates cutting-edge studies in pharmacology, bioinformatics, and materials science, further contributing to his field’s knowledge base.

💻 Bioinformatics and Laboratory Experience:

Prof. Li integrates bioinformatics tools into his research to analyze complex datasets and identify genetic markers associated with drug response. His laboratory is equipped with advanced technologies for pharmacokinetic modeling, epigenetic profiling, and drug formulation analysis, enabling groundbreaking discoveries.

🎓 Training, Workshops, and Oral Presentations:

Prof. Li regularly participates in international conferences, presenting his research findings and engaging with global experts. His oral presentations at prestigious forums highlight advancements in therapeutic drug monitoring (TDM), anesthesiology pharmacy, and intravenous preparation management, solidifying his reputation as a thought leader.

✅ Tasks Completed as a Researcher:

Prof. Li has successfully completed tasks ranging from designing clinical trials to publishing high-impact research. His ability to translate laboratory findings into practical solutions for patient care exemplifies his commitment to improving healthcare outcomes.

🌟 Success Factors and Key Contributions:

Prof. Li’s success stems from his:

  • Collaborative approach in multidisciplinary projects
  • Innovative methodologies in drug evaluation and genetic research
  • Dedication to mentoring young professionals and fostering academic growth

🔬 Ongoing Research Projects:

His current projects delve into:

  • Advanced drug delivery systems to enhance treatment efficacy
  • Epigenetic influences on pharmacodynamics
  • Personalized medicine approaches using genetic profiling

🔍 Conclusion:

Prof. Li Xingang is a distinguished leader in the field of pharmacology, whose contributions span clinical excellence, innovative research, and impactful publications. His work in quantitative and genetic pharmacology, combined with his dedication to mentoring and professional engagement, sets him apart as a visionary in healthcare. His achievements and ongoing endeavors continue to shape the future of precision medicine and pharmacological sciences.

Top Notable Publications:

1. Immune-Related Colitis Induced by Camrelizumab: A Case Report

Authors: Xingang Li

Journal: Journal of Inflammation Research

Year: 2023

2. Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice-

Year: 2023

3. Association of Alcohol Drinking and Helicobacter pylori Infection: A Meta-analysis

Authors: Xingang Li

Journal: Journal of Clinical Gastroenterology

Year: 2023

4. Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice

Year: 2022

5. Association between GNAQ Gene DNA Methylation and Vascular Recurrence in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

Authors: Xingang Li

Journal: Cerebrovascular Diseases (Basel, Switzerland)

Year: 2022

6. Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method

Authors: Xingang Li

Journal: Current Medical Science

Year: 2022

7. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

8. Development of a multivariable clinical prediction model for liposomal doxorubicin-induced cardiotoxicity in adult breast cancer patients: A retrospective multicenter study

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

9. Population pharmacokinetics of methotrexate in pediatric patients with acute lymphoblastic leukemia and malignant lymphoma

Authors: Xingang Li

Journal: Xenobiotica

Year: 2022

10. The clinical population pharmacokinetics, metabolomics, and therapeutic analysis of alkaloids from Alstonia scholaris leaves in acute bronchitis patients

Authors: Xingang Li

Journal: Phytomedicine

Year: 2022